ABMT for early isolated extramedullary relapse of childhood ALL

From July 1987 to July 1991, 12 children underwent AMBT following high-dose cytarabine (HD Ara-C) plus 14.4 Gy hyperfractionated total body irradiation (hyfr-TBI) for early isolated extramedullary relapse of ALL, while in first BM remission. No patient received intrathecal prophylaxis following AMBT...

Full description

Saved in:
Bibliographic Details
Published inBone marrow transplantation (Basingstoke) Vol. 12; no. 1; pp. 37 - 41
Main Authors ROSSETTI, F, MESSINA, C, MINIERO, R, BUSCA, A, SCOTTI, G, CESARO, S, ZANESCO, L, COLLESELLI, P
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing Group 01.07.1993
Subjects
Adolescent
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Bone Marrow Purging
Bone Marrow Transplantation - adverse effects
Bone marrow, stem cells transplantation. Graft versus host reaction
Child
Child, Preschool
Combined Modality Therapy
Cytarabine - administration & dosage
Cytarabine - adverse effects
Female
Humans
Infant
Male
Medical sciences
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - radiotherapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - surgery
Recurrence
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Transplantation, Autologous
Whole-Body Irradiation
Human
Autograft
Relapse
Treatment
Bone marrow
Malignant hemopathy
Acute lymphocytic leukemia
Child
Online AccessGet full text

Cover

More Information
Summary:From July 1987 to July 1991, 12 children underwent AMBT following high-dose cytarabine (HD Ara-C) plus 14.4 Gy hyperfractionated total body irradiation (hyfr-TBI) for early isolated extramedullary relapse of ALL, while in first BM remission. No patient received intrathecal prophylaxis following AMBT. One patient died on day +5 due to sepsis and three patients, two of them transplanted in second and third CNS relapse, respectively, died from BM relapse occurring 1.5, 4 and 5 months after AMBT. Eight of the 12 survive disease-free with a median follow-up of 24 months (range 14-62 months). The toxicity of HD Ara-C plus hyfr-TBI was acceptable and well controlled with supportive therapy. These results suggest that ABMT following HD Ara-C plus hyfr-TBI may eradicate leukemia from extramedullary sites of ALL relapse.
ISSN:0268-3369
1476-5365